Get started

Savara, Inc

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

SVRA chart

Key stats

Market capitalization
334.214MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.26USD

About Savara, Inc

Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Matthew Pauls
Website
savarapharma.com
Headquarters
Austin
Employees
28
Founded
1995
ISIN
US8051111016

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.

Ideas

SVRA BullishI like the several days of consolidation at the 200MA in addition to the bullish pin bar yesterday. The MACD is crossing and the price is still bellow the POC line YTD. I think this is headed into an uptrend. target $1.78, $1.96, $2.25
Long
$SVRA can rise in the next daysContextual immersion trading strategy idea. Savara Inc. operates as an orphan lung disease company. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,77; stop-loss
Long
2
SVRA BIO TECH LongSector: Health Technology Industry: Biotechnology Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Mo
Long
SVRA Break OutThe price took out 5 fibonacci levels (.61, .78, 1, 1.61, 2.61) yesterday with the candle gapping up big. It managed to break thru the descending weekly trend line to close just under the .78 level. Also the MACD is freshly crossed and the RSI is still cool especially considering the monster cand
Long
$SVRA Announces Closing of $130 Million Public OfferingSavara Announces Pricing of Public Offering of Common Stock $SVRA today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara offered t

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.

Financials

Performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.45Fabulous
Learn more
OANDA
OANDA
Forex
4.52Great
Learn more
FOREX.com
FOREX.com
Forex
4.37Fabulous
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.35Fabulous
Learn more

See all brokers 

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more